Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 263 participants.

Also called NCT02653482

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 263 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02653482
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02653482. Randomized; quadruple masking; primary purpose treatment. Start 2016-03-03 (actual); primary completion 2019-06-28 (actual). Results posted on 2021-12-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
Acronym
DEFINE-HF
Condition
Chronic Heart Failure With Reduced Systolic Function
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Dapagliflozin matching placebo
Lead sponsor
Saint Luke's Health System (class: other)

Record details

Record id
cardio:ct-nct02653482
Content hash
362ce8a2ad4eddacfed09da8867169606f7175cbce3138fb877cdf5d63342b78